51350-23-3 Usage
General Description
p-Hydroxybiphenylacetic acid, also known as 4-hydroxy-2-phenylbutanoic acid, is a compound that belongs to the class of biphenyl compounds. It is a derivative of acetic acid and contains a hydroxyl group and a phenyl ring. This chemical is commonly used as a building block in the synthesis of pharmaceuticals and other organic compounds. It has been studied for its potential biological activities, including anti-inflammatory and antioxidant properties. Additionally, p-Hydroxybiphenylacetic acid has been investigated for its potential use in drug delivery systems and as a precursor for the synthesis of fragrance compounds. Overall, it is a versatile chemical with various potential applications in the pharmaceutical and chemical industries.
Check Digit Verification of cas no
The CAS Registry Mumber 51350-23-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,1,3,5 and 0 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 51350-23:
(7*5)+(6*1)+(5*3)+(4*5)+(3*0)+(2*2)+(1*3)=83
83 % 10 = 3
So 51350-23-3 is a valid CAS Registry Number.
51350-23-3Relevant articles and documents
TISSUE FACTOR PRODUCTION INHIBITOR
-
Page/Page column 90, (2010/11/26)
A medicament which has an activity of inhibiting production of tissue factor and comprises an LXR ligand as an active ingredient; and a medicament for treatment and/or prophylaxis of vascular restenosis following angioplasty, endarterectomy, percutaneous transluminal coronary angioplasty (PTCA) or stent implantation, or treatment and/or prophylaxis of blood coagulation diseases, diseases induced by platelet aggregation including stable or unstable angina pectoris, cardiovascular and cerebrovascular diseases including thromboembolism formation diseases accompanying diabetes, rethrombosis following thrombolysis, cerebral ischemic attack, infarction, stroke, ischemia-derived dementia, peripheral artery disease, thromboembolism formation diseases during use of an aorta-coronary artery bypass, glomerulosclerosis, renal embolism, tumor or cancer metastasis, which comprises an LXR ligand as an active ingredient.